Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
Trial Details
- NCT ID
- NCT04716452
- Phase
- PHASE1
- Sponsor
- Keystone Nano, Inc
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Ceramide NanoLiposome (Ceraxa)
- Locations (sample)
- Charlottesville, Virginia, United States|38.02931,-78.47668
Key Eligibility Criteria
- Signed informed consent is obtained prior to conducting any study-specific screening procedures.
- Willing and able to understand the nature of this study and to comply with the study and follow-up procedures.
- Age and Disease: ≥ 18 years of age with refractory or relapsed AML
- Refractory AML: Patients who fail to achieve a complete remission (CR) or a complete remission with incomplete count recovery (CRi) after one or mo…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →